Clinical proton MR spectroscopy in central nervous system disorders

Gülin Öz, Jeffry R. Alger, Peter B. Barker, Robert Bartha, Alberto Bizzi, Chris Boesch, Patrick J. Bolan, Kevin M. Brindle, Cristina Cudalbu, Alp Dinçer, Ulrike Dydak, Uzay E. Emir, Jens Frahm, Ramón Gilberto González, Stephan Gruber, Rolf Gruetter, Rakesh K. Gupta, Arend Heerschap, Anke Henning, Hoby P. HetheringtonFranklyn A. Howe, Petra S. Hüppi, Ralph E. Hurd, Kejal Kantarci, Dennis W.J. Klomp, Roland Kreis, Marijn J. Kruiskamp, Martin O. Leach, Alexander P. Lin, Peter R. Luijten, Małgorzata Marjańska, Andrew A. Maudsley, Dieter J. Meyerhoff, Carolyn E. Mountford, Sarah J. Nelson, Necmettin Pamir, Jullie W. Pan, Andrew C. Peet, Harish Poptani, Harish Poptani, Stefan Posse, Petra J.W. Pouwels, Eva Maria Ratai, Brian D. Ross, Tom W.J. Scheenen, Christian Schuster, Ian C.P. Smith, Brian J. Soher, Ivan Tkáč, Daniel B. Vigneron, Risto A. Kauppinen

Research output: Contribution to journalReview articlepeer-review

307 Scopus citations


A large body of published work shows that proton (hydrogen 1 [ 1H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of 1H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of 1H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which 1H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units.

Original languageEnglish (US)
Pages (from-to)658-679
Number of pages22
Issue number3
StatePublished - Mar 5 2014

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Clinical proton MR spectroscopy in central nervous system disorders'. Together they form a unique fingerprint.

Cite this